Net margin is calculated as Net Income divided by its Revenue. AIM ImmunoTech's Net Income for the
three
months ended in Mar. 2026 was $-3.02 Mil. AIM ImmunoTech's Revenue for the
three
months ended in Mar. 2026 was $0.02 Mil. Therefore, AIM ImmunoTech's net margin for the quarter that ended in Mar. 2026 was -13,740.91%.
The historical rank and industry rank for AIM ImmunoTech's Net Margin % or its related term are showing as below:
AIM'
s Net Margin % Range Over the Past 10 Years
Min: -15861.36 Med: -9511.3 Max: -1889.93
Current: -14123.4
AIM's Net Margin % is ranked worse than 94.29% of 945
companies
in the Biotechnology industry
Industry Median: -89.33
vs AIM: -14123.40
AIM ImmunoTech (AMEX:AIM) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
AIM ImmunoTech Net Margin % Related Terms
AIM ImmunoTech Net Margin % Historical Data
* Premium members only.
The historical data trend for AIM ImmunoTech's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AIM ImmunoTech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AIM ImmunoTech Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Net Margin % distribution charts can be found below:
* The bar in red indicates where AIM ImmunoTech's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AIM ImmunoTech (AIM) has a Net Margin % of -13,740.91% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on AIM ImmunoTech and its competitors. According to the industry distribution chart, AIM ImmunoTech ranks #891 out of 945 companies in the Biotechnology industry, placing it in the top 94.3%.
Is AIM ImmunoTech's Net Margin % too high?
AIM ImmunoTech's current Net Margin % is -13,740.91%. Based on the distribution chart, AIM ImmunoTech ranks #891 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, AIM ImmunoTech has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AIM ImmunoTech's Net Margin % compare to BGMS and FBLG?
According to the Biotechnology industry distribution chart, AIM ImmunoTech ranks #891 out of 945 companies for Net Margin %. This places AIM ImmunoTech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on AIM ImmunoTech and its competitors. AIM ImmunoTech's current Net Margin % is -13,740.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AIM ImmunoTech stock overvalued right now?
Based on GuruFocus' analysis, AIM ImmunoTech (AIM) is currently considered Possible Value Trap. The stock's GF Value™ is $2.69, compared to a current price of $0.31 — trading 88.4% below its estimated fair value. The current Net Margin % is -13,740.91%. AIM ImmunoTech's overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For AIM ImmunoTech (AIM), the current Net Margin % is -13,740.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AIM ImmunoTech (AIM) Overvalued in 2026?
Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued.
The current stock price of $0.31 is trading 88.4% below its estimated GF Value™ of $2.69.
GuruFocus considers AIM ImmunoTech to be Possible Value Trap.
Key valuation signals for AIM:
Net Margin %: -13,740.91%
GF Value™: $2.69 vs. price of $0.31 (88.4% below fair value)
No single metric tells the full story. See the AIM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score
Get the complete analysis for AIM
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIM has been successfully added to your 
